{"transactions":[{"id":948749,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:11:54.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001197018-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000119701826000002/edgardoc.xml","form_type":"4"}},{"id":948748,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:11:54.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1714,"source":{"system":"sec-edgar","filing":"0001197018-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000119701826000002/edgardoc.xml","form_type":"4"}},{"id":1312119,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-01-06T21:12:14.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":1958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1958,"derivative":{"exercise_price":719.37,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":1958},"source":{"system":"sec-edgar","filing":"0001968202-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000010/edgardoc.xml","form_type":"4"}},{"id":1312118,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T21:12:14.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1559,"source":{"system":"sec-edgar","filing":"0001968202-25-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000010/edgardoc.xml","form_type":"4"}},{"id":1440874,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-08-05T16:20:32.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":46322},"source":{"system":"sec-edgar","filing":"0000950170-24-090789","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090789/ownership.xml","form_type":"4"}},{"id":1440873,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:20:32.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4809418,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4809418},"source":{"system":"sec-edgar","filing":"0000950170-24-090789","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090789/ownership.xml","form_type":"4"}},{"id":1440872,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:20:32.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10290,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090789/ownership.xml","form_type":"4"}},{"id":1440871,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:20:32.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15638,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":10290,"source":{"system":"sec-edgar","filing":"0000950170-24-090789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090789/ownership.xml","form_type":"4"}},{"id":1460154,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T16:05:03.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":2177417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-081490","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024081490/ownership.xml","form_type":"4"}},{"id":1460153,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T16:05:03.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":41.1814,"value":1029535.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.85 to $41.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 10,290 unvested Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of the Issuer's common stock.  These RSUs shall vest upon the earlier of: (i) June 5, 2025, or (ii) the 2025 annual meeting of stockholders of the Company."}],"balance_after":25928,"source":{"system":"sec-edgar","filing":"0000950170-24-081490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024081490/ownership.xml","form_type":"4"}},{"id":1460152,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T16:05:03.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":3.5,"value":87500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 10,290 unvested Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of the Issuer's common stock.  These RSUs shall vest upon the earlier of: (i) June 5, 2025, or (ii) the 2025 annual meeting of stockholders of the Company."}],"balance_after":50928,"source":{"system":"sec-edgar","filing":"0000950170-24-081490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024081490/ownership.xml","form_type":"4"}},{"id":1486984,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T16:34:34.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10290,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."}],"balance_after":25928,"source":{"system":"sec-edgar","filing":"0000950170-24-070736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024070736/ownership.xml","form_type":"4"}},{"id":1490159,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T16:05:11.000Z","date":"2024-06-03","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2202417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-069284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024069284/ownership.xml","form_type":"4"}},{"id":1490158,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T16:05:11.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":40.6104,"value":2030520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.29 to $40.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15638,"source":{"system":"sec-edgar","filing":"0000950170-24-069284","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024069284/ownership.xml","form_type":"4"}},{"id":1490157,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T16:05:11.000Z","date":"2024-06-03","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."}],"balance_after":65638,"source":{"system":"sec-edgar","filing":"0000950170-24-069284","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024069284/ownership.xml","form_type":"4"}},{"id":1517623,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-14T17:16:43.000Z","date":"2024-05-10","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2252417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-059788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024059788/ownership.xml","form_type":"4"}},{"id":1517622,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-14T17:16:43.000Z","date":"2024-05-10","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":42.1025,"value":2105125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $42.005 to $42.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15638,"source":{"system":"sec-edgar","filing":"0000950170-24-059788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024059788/ownership.xml","form_type":"4"}},{"id":1517621,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-14T17:16:43.000Z","date":"2024-05-10","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."}],"balance_after":65638,"source":{"system":"sec-edgar","filing":"0000950170-24-059788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024059788/ownership.xml","form_type":"4"}},{"id":1549921,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T16:15:07.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2302417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-041073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024041073/ownership.xml","form_type":"4"}},{"id":1549920,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T16:15:07.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":42.3328,"value":2116640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $42.20 to $42.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15638,"source":{"system":"sec-edgar","filing":"0000950170-24-041073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024041073/ownership.xml","form_type":"4"}},{"id":1549919,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T16:15:07.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."}],"balance_after":65638,"source":{"system":"sec-edgar","filing":"0000950170-24-041073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024041073/ownership.xml","form_type":"4"}},{"id":1591917,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T16:15:10.000Z","date":"2024-03-04","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2352417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-027156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024027156/ownership.xml","form_type":"4"}},{"id":1591916,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-06T16:15:10.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":41.011,"value":2050550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.81 to $41.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15638,"source":{"system":"sec-edgar","filing":"0000950170-24-027156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024027156/ownership.xml","form_type":"4"}},{"id":1591915,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-06T16:15:10.000Z","date":"2024-03-04","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."}],"balance_after":65638,"source":{"system":"sec-edgar","filing":"0000950170-24-027156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024027156/ownership.xml","form_type":"4"}},{"id":1603399,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T17:49:33.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2402417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-025036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024025036/ownership.xml","form_type":"4"}},{"id":1603398,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T17:49:33.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":41.1578,"value":2057890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.00 to $41.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15638,"source":{"system":"sec-edgar","filing":"0000950170-24-025036","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024025036/ownership.xml","form_type":"4"}},{"id":1603397,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T17:49:33.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."}],"balance_after":65638,"source":{"system":"sec-edgar","filing":"0000950170-24-025036","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024025036/ownership.xml","form_type":"4"}},{"id":1653575,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-02-08T19:14:55.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":15440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":46322,"derivative":{"underlying":"Common Stock","underlying_shares":15440},"source":{"system":"sec-edgar","filing":"0000950170-24-012953","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024012953/ownership.xml","form_type":"4"}},{"id":1653574,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-08T19:14:55.000Z","date":"2024-02-07","kind":"sale","planned":false,"acquired":false,"shares":2506,"price":41.5441,"value":104109.5146,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.42 to $41.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15638,"source":{"system":"sec-edgar","filing":"0000950170-24-012953","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024012953/ownership.xml","form_type":"4"}},{"id":1653573,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-08T19:14:55.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":15440,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's common stock."}],"balance_after":18144,"source":{"system":"sec-edgar","filing":"0000950170-24-012953","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024012953/ownership.xml","form_type":"4"}},{"id":1689471,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-04T21:11:27.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1607,"derivative":{"exercise_price":888.34,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":1607},"source":{"system":"sec-edgar","filing":"0001968202-24-000029","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000029/edgardoc.xml","form_type":"4"}},{"id":1689470,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:11:27.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1393,"source":{"system":"sec-edgar","filing":"0001968202-24-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000029/edgardoc.xml","form_type":"4"}},{"id":1688050,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T16:15:08.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2452417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-001864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024001864/ownership.xml","form_type":"4"}},{"id":1688049,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T16:15:08.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":42.2363,"value":2111815.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $42.15 to $42.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-24-001864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024001864/ownership.xml","form_type":"4"}},{"id":1688048,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T16:15:08.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000950170-24-001864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024001864/ownership.xml","form_type":"4"}},{"id":1739208,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-16T16:15:14.000Z","date":"2023-11-14","kind":"exercise","planned":false,"acquired":false,"shares":22824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2502417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":22824},"source":{"system":"sec-edgar","filing":"0000950170-23-064517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023064517/ownership.xml","form_type":"4"}},{"id":1739207,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T16:15:14.000Z","date":"2023-11-14","kind":"sale","planned":false,"acquired":false,"shares":22824,"price":25.1251,"value":573455.2824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.52. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-064517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023064517/ownership.xml","form_type":"4"}},{"id":1739206,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T16:15:14.000Z","date":"2023-11-14","kind":"exercise","planned":false,"acquired":true,"shares":22824,"price":3.5,"value":79884.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":25528,"source":{"system":"sec-edgar","filing":"0000950170-23-064517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023064517/ownership.xml","form_type":"4"}},{"id":1745775,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-09T17:03:43.000Z","date":"2023-11-08","kind":"exercise","planned":false,"acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2525241,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0000950170-23-062217","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023062217/ownership.xml","form_type":"4"}},{"id":1745774,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-09T17:03:43.000Z","date":"2023-11-07","kind":"exercise","planned":false,"acquired":false,"shares":27076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2525341,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":27076},"source":{"system":"sec-edgar","filing":"0000950170-23-062217","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023062217/ownership.xml","form_type":"4"}},{"id":1745773,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T17:03:43.000Z","date":"2023-11-08","kind":"sale","planned":false,"acquired":false,"shares":100,"price":25.16,"value":2516.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-062217","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023062217/ownership.xml","form_type":"4"}},{"id":1745772,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T17:03:43.000Z","date":"2023-11-08","kind":"exercise","planned":false,"acquired":true,"shares":100,"price":3.5,"value":350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":2804,"source":{"system":"sec-edgar","filing":"0000950170-23-062217","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023062217/ownership.xml","form_type":"4"}},{"id":1745771,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T17:03:43.000Z","date":"2023-11-07","kind":"sale","planned":false,"acquired":false,"shares":27076,"price":25.0242,"value":677555.2392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-062217","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023062217/ownership.xml","form_type":"4"}},{"id":1745770,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-09T17:03:43.000Z","date":"2023-11-07","kind":"exercise","planned":false,"acquired":true,"shares":27076,"price":3.5,"value":94766.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":29780,"source":{"system":"sec-edgar","filing":"0000950170-23-062217","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023062217/ownership.xml","form_type":"4"}},{"id":1748747,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-06T17:12:11.000Z","date":"2023-11-03","kind":"exercise","planned":false,"acquired":false,"shares":61401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":2552417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":61401},"source":{"system":"sec-edgar","filing":"0000950170-23-059520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023059520/ownership.xml","form_type":"4"}},{"id":1748746,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-06T17:12:11.000Z","date":"2023-11-02","kind":"exercise","planned":false,"acquired":false,"shares":38599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":2613818,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":38599},"source":{"system":"sec-edgar","filing":"0000950170-23-059520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023059520/ownership.xml","form_type":"4"}},{"id":1748745,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-06T17:12:11.000Z","date":"2023-11-03","kind":"sale","planned":false,"acquired":false,"shares":61401,"price":25.4305,"value":1561458.1305,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.03 to $25.83. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-059520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023059520/ownership.xml","form_type":"4"}},{"id":1748744,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-06T17:12:11.000Z","date":"2023-11-03","kind":"exercise","planned":false,"acquired":true,"shares":61401,"price":3.5,"value":214903.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":64105,"source":{"system":"sec-edgar","filing":"0000950170-23-059520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023059520/ownership.xml","form_type":"4"}},{"id":1748743,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-06T17:12:11.000Z","date":"2023-11-02","kind":"sale","planned":false,"acquired":false,"shares":38599,"price":25.1882,"value":972239.3318,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-059520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023059520/ownership.xml","form_type":"4"}},{"id":1748742,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-06T17:12:11.000Z","date":"2023-11-02","kind":"exercise","planned":false,"acquired":true,"shares":38599,"price":3.5,"value":135096.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":41303,"source":{"system":"sec-edgar","filing":"0000950170-23-059520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023059520/ownership.xml","form_type":"4"}},{"id":1784754,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-08T16:35:08.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2652417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-047297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023047297/ownership.xml","form_type":"4"}},{"id":1784753,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:35:08.000Z","date":"2023-09-07","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":24.0683,"value":1203415.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $23.97 to $24.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-047297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023047297/ownership.xml","form_type":"4"}},{"id":1784752,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T16:35:08.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000950170-23-047297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023047297/ownership.xml","form_type":"4"}},{"id":1830354,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:41:54.000Z","date":"2023-07-11","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2702417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-032878","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023032878/ownership.xml","form_type":"4"}},{"id":1830353,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-13T17:41:54.000Z","date":"2023-07-11","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":30.0268,"value":1501340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 - $30.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-032878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023032878/ownership.xml","form_type":"4"}},{"id":1830352,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-13T17:41:54.000Z","date":"2023-07-11","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000950170-23-032878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023032878/ownership.xml","form_type":"4"}},{"id":1867281,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:12:46.000Z","date":"2023-06-01","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2752417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-026502","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023026502/ownership.xml","form_type":"4"}},{"id":1867280,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-06-05T20:12:46.000Z","date":"2023-06-01","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":32.6014,"value":1630070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 - $33.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-026502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023026502/ownership.xml","form_type":"4"}},{"id":1867279,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-06-05T20:12:46.000Z","date":"2023-06-01","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000950170-23-026502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023026502/ownership.xml","form_type":"4"}},{"id":1901049,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-08T16:24:12.000Z","date":"2023-05-04","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2802417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-012418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323012418/doc4.xml","form_type":"4"}},{"id":1901048,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-05-08T16:24:12.000Z","date":"2023-05-04","kind":"sale","planned":true,"acquired":false,"shares":300,"price":32.93,"value":9879.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000899243-23-012418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323012418/doc4.xml","form_type":"4"}},{"id":1901047,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-05-08T16:24:12.000Z","date":"2023-05-04","kind":"sale","planned":true,"acquired":false,"shares":12132,"price":31.7579,"value":385286.8428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.63 - $32.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3004,"source":{"system":"sec-edgar","filing":"0000899243-23-012418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323012418/doc4.xml","form_type":"4"}},{"id":1901046,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-05-08T16:24:12.000Z","date":"2023-05-04","kind":"sale","planned":true,"acquired":false,"shares":37568,"price":31.3636,"value":1178267.7248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.63 - $31.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15136,"source":{"system":"sec-edgar","filing":"0000899243-23-012418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323012418/doc4.xml","form_type":"4"}},{"id":1901045,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-05-08T16:24:12.000Z","date":"2023-05-04","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000899243-23-012418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323012418/doc4.xml","form_type":"4"}},{"id":1920358,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-13T16:48:30.000Z","date":"2023-04-11","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2852417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-012731","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023012731/ownership.xml","form_type":"4"}},{"id":1920357,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-04-13T16:48:30.000Z","date":"2023-04-11","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":25.0626,"value":1253130.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000950170-23-012731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023012731/ownership.xml","form_type":"4"}},{"id":1920356,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-04-13T16:48:30.000Z","date":"2023-04-11","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000950170-23-012731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023012731/ownership.xml","form_type":"4"}},{"id":1969297,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T16:15:28.000Z","date":"2023-03-03","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2902417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-23-007176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323007176/doc4.xml","form_type":"4"}},{"id":1969296,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T16:15:28.000Z","date":"2023-03-02","kind":"exercise","acquired":false,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2905417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0000899243-23-007176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323007176/doc4.xml","form_type":"4"}},{"id":1969295,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-03-06T16:15:28.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":3000,"price":27.19,"value":81570.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000899243-23-007176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323007176/doc4.xml","form_type":"4"}},{"id":1969294,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-03-06T16:15:28.000Z","date":"2023-03-03","kind":"exercise","acquired":true,"shares":3000,"price":3.5,"value":10500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":5704,"source":{"system":"sec-edgar","filing":"0000899243-23-007176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323007176/doc4.xml","form_type":"4"}},{"id":1969293,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-03-06T16:15:28.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":47000,"price":27.1144,"value":1274376.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.62 - $27.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000899243-23-007176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323007176/doc4.xml","form_type":"4"}},{"id":1969292,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-03-06T16:15:28.000Z","date":"2023-03-02","kind":"exercise","acquired":true,"shares":47000,"price":3.5,"value":164500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":49704,"source":{"system":"sec-edgar","filing":"0000899243-23-007176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323007176/doc4.xml","form_type":"4"}},{"id":2026613,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-08T20:27:24.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2952417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-004360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004360/doc4.xml","form_type":"4"}},{"id":2026612,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Restricted Stock Units","published_at":"2023-02-08T20:27:24.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":61762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":61762,"derivative":{"underlying":"Common Stock","underlying_shares":61762},"source":{"system":"sec-edgar","filing":"0000899243-23-004360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004360/doc4.xml","form_type":"4"}},{"id":2026611,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-08T20:27:24.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":243042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":243042,"derivative":{"exercise_price":34.41,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":243042},"source":{"system":"sec-edgar","filing":"0000899243-23-004360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004360/doc4.xml","form_type":"4"}},{"id":2026610,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-02-08T20:27:24.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":7942,"price":33.5745,"value":266648.679,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.44 - $34.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000899243-23-004360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004360/doc4.xml","form_type":"4"}},{"id":2026609,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-02-08T20:27:24.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":42058,"price":33.0437,"value":1389751.9346,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 - $33.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10646,"source":{"system":"sec-edgar","filing":"0000899243-23-004360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004360/doc4.xml","form_type":"4"}},{"id":2026608,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-02-08T20:27:24.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000899243-23-004360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004360/doc4.xml","form_type":"4"}},{"id":2060552,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-06T17:04:19.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":3002417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-001184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323001184/doc4.xml","form_type":"4"}},{"id":2060551,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-01-06T17:04:19.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":500,"price":30.732,"value":15366.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.64 - $30.885. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000899243-23-001184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323001184/doc4.xml","form_type":"4"}},{"id":2060550,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-01-06T17:04:19.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":49500,"price":29.9294,"value":1481505.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.53 - $30.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3204,"source":{"system":"sec-edgar","filing":"0000899243-23-001184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323001184/doc4.xml","form_type":"4"}},{"id":2060549,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2023-01-06T17:04:19.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":50000,"price":3.5,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."}],"balance_after":52704,"source":{"system":"sec-edgar","filing":"0000899243-23-001184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323001184/doc4.xml","form_type":"4"}},{"id":2064231,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-05T21:15:04.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1929,"derivative":{"exercise_price":725.89,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":1929},"source":{"system":"sec-edgar","filing":"0001883850-23-000012","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000012/edgardoc.xml","form_type":"4"}},{"id":2064230,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T21:15:04.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1258,"source":{"system":"sec-edgar","filing":"0001883850-23-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000012/edgardoc.xml","form_type":"4"}},{"id":2074621,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"exercise","acquired":false,"shares":3613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":482.68,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":3613},"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074620,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"exercise","acquired":false,"shares":2145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":374.12,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":2145},"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074619,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":311,"price":716.08,"value":222700.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price."}],"balance_after":1093,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074618,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":2266,"price":715.48,"value":1621277.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price."}],"balance_after":1404,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074617,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":1022,"price":714.61,"value":730331.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price."}],"balance_after":3670,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074616,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":1198,"price":713.66,"value":854964.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price."}],"balance_after":4692,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074615,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":100,"price":711.95,"value":71195.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":5890,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074614,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":679,"price":710.63,"value":482517.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price."}],"balance_after":5990,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074613,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":1,"price":709.92,"value":709.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6669,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074612,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":181,"price":707.87,"value":128124.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6670,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074611,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"exercise","acquired":true,"shares":3613,"price":482.68,"value":1743922.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6851,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2074610,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T21:10:22.000Z","date":"2022-12-28","kind":"exercise","acquired":true,"shares":2145,"price":374.12,"value":802487.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":3238,"source":{"system":"sec-edgar","filing":"0001883850-22-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000143/edgardoc.xml","form_type":"4"}},{"id":2088107,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-13T16:44:18.000Z","date":"2022-12-09","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":3052417,"derivative":{"exercise_price":3.5,"expiration_date":"2028-12-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-22-038323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322038323/doc4.xml","form_type":"4"}},{"id":2088106,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2022-12-13T16:44:18.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":5145,"price":27.0932,"value":139394.514,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 - $27.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2704,"source":{"system":"sec-edgar","filing":"0000899243-22-038323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322038323/doc4.xml","form_type":"4"}},{"id":2088105,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":17510,"kind":"person","name":"COLES N ANTHONY","position":1,"cik":"0001197018","reported_name":"COLES N ANTHONY","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Common Stock","published_at":"2022-12-13T16:44:18.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":44855,"price":26.617,"value":1193905.535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.04 - $27.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7849,"source":{"system":"sec-edgar","filing":"0000899243-22-038323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322038323/doc4.xml","form_type":"4"}}],"next_cursor":"2022-12-13T16:44:18.000000Z,2088105"}